A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Ana Ruiz-Garcia D Ross Camidge Pasi A Jänne Giuseppe Giaccone Karen L. Reckamp |
| Publication date | February 5, 2014 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |